These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38425096)

  • 1. CAMP-B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance.
    Lee HW; Yip TC; Wong VW; Lim YS; Chan HL; Ahn SH; Wong GL; Choi J
    Aliment Pharmacol Ther; 2024 May; 59(10):1223-1235. PubMed ID: 38425096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance.
    Kim GA; Lee HC; Kim MJ; Ha Y; Park EJ; An J; Lee D; Shim JH; Kim KM; Lim YS
    J Hepatol; 2015 May; 62(5):1092-9. PubMed ID: 25445399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    Yang H; Bae SH; Nam H; Lee HL; Lee SW; Yoo SH; Song MJ; Kwon JH; Nam SW; Choi JY; Yoon SK; Jang JW
    J Hepatol; 2022 Sep; 77(3):632-641. PubMed ID: 35398462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk and Risk Score Performance of Hepatocellular Carcinoma Development in Patients With Hepatitis B Surface Antigen Seroclearance.
    Park Y; Lee JH; Sinn DH; Park JY; Kim MA; Kim YJ; Yoon JH; Kim DY; Ahn SH; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Clin Transl Gastroenterol; 2021 Jan; 12(1):e00290. PubMed ID: 33433118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    Yip TC; Chan HL; Wong VW; Tse YK; Lam KL; Wong GL
    J Hepatol; 2017 Nov; 67(5):902-908. PubMed ID: 28652084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance.
    Fung J; Cheung KS; Wong DK; Mak LY; To WP; Seto WK; Lai CL; Yuen MF
    Hepatology; 2018 Aug; 68(2):462-472. PubMed ID: 29534307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Long-Term Clinical Outcomes Between Spontaneous and Therapy-Induced HBsAg Seroclearance.
    Choi J; Yoo S; Lim YS
    Hepatology; 2021 Jun; 73(6):2155-2166. PubMed ID: 33131063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
    Yip TC; Wong GL; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW
    J Hepatol; 2019 Mar; 70(3):361-370. PubMed ID: 30367899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Diabetes and Glycemic Control on Risk of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen.
    Cheuk-Fung Yip T; Wai-Sun Wong V; Lik-Yuen Chan H; Tse YK; Pik-Shan Kong A; Long-Yan Lam K; Chung-Yan Lui G; Lai-Hung Wong G
    Clin Gastroenterol Hepatol; 2018 May; 16(5):765-773.e2. PubMed ID: 29246694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss.
    Yip TC; Wong VW; Lai MS; Lai JC; Hui VW; Liang LY; Tse YK; Chan HL; Wong GL
    J Hepatol; 2023 Mar; 78(3):524-533. PubMed ID: 36463985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review with meta-analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance.
    Liu F; Wang XW; Chen L; Hu P; Ren H; Hu HD
    Aliment Pharmacol Ther; 2016 Jun; 43(12):1253-61. PubMed ID: 27117732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HBsAg seroclearance in chronic hepatitis B: implications for hepatocellular carcinoma.
    Kim JH; Lee YS; Lee HJ; Yoon E; Jung YK; Jong ES; Lee BJ; Seo YS; Yim HJ; Yeon JE; Park JJ; Kim JS; Bak YT; Byun KS
    J Clin Gastroenterol; 2011 Jan; 45(1):64-8. PubMed ID: 20535028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma.
    Yuen MF; Wong DK; Fung J; Ip P; But D; Hung I; Lau K; Yuen JC; Lai CL
    Gastroenterology; 2008 Oct; 135(4):1192-9. PubMed ID: 18722377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Fatty Liver and Cirrhosis, Hepatocellular Carcinoma, and Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B.
    Li J; Yang HI; Yeh ML; Le MH; Le AK; Yeo YH; Dai CY; Barnett S; Zhang JQ; Huang JF; Trinh HN; Wong C; Wong C; Hoang JK; Cheung R; Yu ML; Nguyen MH
    J Infect Dis; 2021 Jul; 224(2):294-302. PubMed ID: 33249474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features of HBsAg seroclearance in hepatitis B virus carriers in South Korea: A retrospective longitudinal study.
    Park YM; Lee SG
    World J Gastroenterol; 2016 Nov; 22(44):9836-9843. PubMed ID: 27956808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue-induced hepatitis B surface antigen loss.
    Yip TC; Wong VW; Tse YK; Liang LY; Hui VW; Zhang X; Li GL; Lui GC; Chan HL; Wong GL
    Aliment Pharmacol Ther; 2021 Jan; 53(2):321-331. PubMed ID: 33222272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review of risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    Kuang XJ; Jia RR; Huo RR; Yu JJ; Wang JJ; Xiang BD; Li LQ; Peng Z; Zhong JH
    J Viral Hepat; 2018 Sep; 25(9):1026-1037. PubMed ID: 29624821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral Load-Based Prediction of Hepatocellular Carcinoma Risk in Noncirrhotic Patients With Chronic Hepatitis B : A Multinational Study for the Development and External Validation of a New Prognostic Model.
    Kim GA; Lim YS; Han S; Choi GH; Choi WM; Choi J; Sinn DH; Paik YH; Lee JH; Lee YB; Cho JY; Heo NY; Yuen MF; Wong VW; Chan SL; Yang HI; Chen CJ
    Ann Intern Med; 2024 Oct; 177(10):1308-1318. PubMed ID: 39284185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance.
    Lee HW; Lee JI; Kim S; Kim S; Chang HY; Lee KS
    BMC Gastroenterol; 2020 Apr; 20(1):113. PubMed ID: 32305059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis.
    Yang HI; Tseng TC; Liu J; Lee MH; Liu CJ; Su TH; Batrla-Utermann R; Chan HL; Kao JH; Chen CJ
    Clin Gastroenterol Hepatol; 2016 Mar; 14(3):461-468.e2. PubMed ID: 26598229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.